Bold vision
Global ambition
Board of Directors
Mr. Glenn Saldanha
Chairman & Managing Director
Mr. Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals, a USD 1.6 billion company with growing presence across more than 80 countries. A visionary leader, he has been instrumental in transforming Glenmark into a diversified, innovation- led pharmaceutical company recognized on the global stage.
Under his leadership, Glenmark has built strong capabilities in R&D, biologics, and specialty therapies, becoming one of the few Indian pharma companies with novel molecules in global clinical development. Through the company’s biotech arm, Ichnos Glenmark Innovation (IGI), he has enabled breakthrough research in oncology and immunology to reach patients worldwide, shaping India’s position on the global pharmaceutical innovation map.
Honored with the EY Entrepreneur of the Year Award in 2017, Mr. Saldanha is widely regarded as a thought leader in the pharmaceutical sector. He continues to champion accessible innovation, advanced manufacturing, and strategic global partnerships to deliver lasting value for patients and healthcare systems. A pharmacy graduate from Mumbai University and an MBA from NYU’s Leonard Stern School of Business, he brings a unique blend of scientific acumen and strategic foresight, strengthened by his early experiences at Eli Lilly and PwC in the U.S.
Mr. Glenn Saldanha
Chairman & Managing Director
Mr. Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals, a USD 1.6 billion company with growing presence across more than 80 countries. A visionary leader, he has been instrumental in transforming Glenmark into a diversified, innovation- led pharmaceutical company recognized on the global stage.
Under his leadership, Glenmark has built strong capabilities in R&D, biologics, and specialty therapies, becoming one of the few Indian pharma companies with novel molecules in global clinical development. Through the company’s biotech arm, Ichnos Glenmark Innovation (IGI), he has enabled breakthrough research in oncology and immunology to reach patients worldwide, shaping India’s position on the global pharmaceutical innovation map.
Honored with the EY Entrepreneur of the Year Award in 2017, Mr. Saldanha is widely regarded as a thought leader in the pharmaceutical sector. He continues to champion accessible innovation, advanced manufacturing, and strategic global partnerships to deliver lasting value for patients and healthcare systems. A pharmacy graduate from Mumbai University and an MBA from NYU’s Leonard Stern School of Business, he brings a unique blend of scientific acumen and strategic foresight, strengthened by his early experiences at Eli Lilly and PwC in the U.S.
Ms. Cheryl Pinto
Executive Director – Corporate Services
Mrs. Cherylann Pinto has been Director of Corporate Services at Glenmark Pharmaceuticals since October 1999 and is an Executive Member of the Board.
With over three decades of experience in the pharmaceutical field, she currently heads the Company’s corporate services, which comprises human resources (HR), administration, insurance, information technology (IT), corporate communications, and corporate social responsibility (CSR) functions.
Prior to Glenmark, she was an entrepreneur, establishing a pharmaceutical company where she served as Managing Director for ten years.
Corporate Services
Ms. Cheryl Pinto
Executive Director – Corporate Services
Mrs. Cherylann Pinto has been Director of Corporate Services at Glenmark Pharmaceuticals since October 1999 and is an Executive Member of the Board.
With over three decades of experience in the pharmaceutical field, she currently heads the Company’s corporate services, which comprises human resources (HR), administration, insurance, information technology (IT), corporate communications, and corporate social responsibility (CSR) functions.
Prior to Glenmark, she was an entrepreneur, establishing a pharmaceutical company where she served as Managing Director for ten years.
Mr. Anurag Mantri
Executive Director & Global Chief Financial Officer
Mr. Anurag Mantri leads the global finance, corporate affairs and governance functions at Glenmark Pharmaceuticals. With over three decades of multifaceted experience across leading Indian and global organizations, he brings deep expertise in strategic leadership, enterprise transformation, and financial excellence.
He has held senior leadership roles at Schneider Electric, Cairn plc, HCL Tech, SRF, and L&T. Prior to joining Glenmark, he served on the Board of Jindal Stainless as Executive Director & Group CFO, where he led one of India’s most recognized corporate transformations.
A recipient of the Forbes India New Age CFO recognition, he is also a respected voice at leading forums on business transformation, automation & digitization, ESG, and corporate governance.
Global Chief Financial Officer
Mr. Anurag Mantri
Executive Director & Global Chief Financial Officer
Mr. Anurag Mantri leads the global finance, corporate affairs and governance functions at Glenmark Pharmaceuticals. With over three decades of multifaceted experience across leading Indian and global organizations, he brings deep expertise in strategic leadership, enterprise transformation, and financial excellence.
He has held senior leadership roles at Schneider Electric, Cairn plc, HCL Tech, SRF, and L&T. Prior to joining Glenmark, he served on the Board of Jindal Stainless as Executive Director & Group CFO, where he led one of India’s most recognized corporate transformations.
A recipient of the Forbes India New Age CFO recognition, he is also a respected voice at leading forums on business transformation, automation & digitization, ESG, and corporate governance.
Mr. Dipankar Bhattacharjee
Non-Executive Independent Director
Mr. Dipankar Bhattacharjee is a Non-Executive Independent Director at Glenmark Pharmaceuticals. He has over three decades of global experience, leading healthcare businesses across North America, Europe, APAC and MEA. He was President & CEO – Global Generics Medicines at Teva Pharmaceutical Industries.
Prior to that, he held senior leadership roles at Bausch & Lomb, Bank of America, and Nestlé. He currently advises investors on mergers and acquisitions in the European pharmaceutical space.
Mr. Dipankar Bhattacharjee
Non-Executive Independent Director
Mr. Dipankar Bhattacharjee is a Non-Executive Independent Director at Glenmark Pharmaceuticals. He has over three decades of global experience, leading healthcare businesses across North America, Europe, APAC and MEA. He was President & CEO – Global Generics Medicines at Teva Pharmaceutical Industries.
Prior to that, he held senior leadership roles at Bausch & Lomb, Bank of America, and Nestlé. He currently advises investors on mergers and acquisitions in the European pharmaceutical space.
Ms. Saira Ramasastry
Non-Executive Independent Director
Ms. Saira Ramasastry is a Non-Executive Independent Director at Glenmark Pharmaceuticals.
She has close to three decades of experience in the Life Sciences industry, successfully building companies as an advisor, board member and operational executive.
She is the Founder and Managing Partner of Life Sciences Advisory, LLC.
Ms. Saira Ramasastry
Non-Executive Independent Director
Ms. Saira Ramasastry is a Non-Executive Independent Director at Glenmark Pharmaceuticals.
She has close to three decades of experience in the Life Sciences industry, successfully building companies as an advisor, board member and operational executive.
She is the Founder and Managing Partner of Life Sciences Advisory, LLC.
Ms. Patricia S. Andrews
Non-Executive Independent Director
Ms. Andrews is an accomplished biopharmaceutical executive and public company board member with a track record of success in corporate strategy, new product commercializations, and business development. Ms. Andrews previously served as Chief Executive Officer for Sumitomo Pharma Oncology, Inc. (SMP Oncology), a clinical-stage research and development biopharmaceutical company, and Global Head of Oncology, Executive Officer for Sumitomo Pharma Co., Ltd. from 2017 to 2023. Under her leadership, the organization completed three Phase 3 trials and expanded the clinical pipeline from two programs to eight.
Prior to SMP Oncology, Ms. Andrews served as Chief Commercial Officer for Incyte and led the organization through the launch preparations and introduction of Jakafi®, the company’s first commercial product, a novel, first-in-class, first-in-disease agent for the treatment of myelofibrosis. While with Incyte, she also steered landmark licensing arrangements with Novartis and Eli Lilly that were critically important to fund the company’s long-term trajectory.
Prior to Incyte, Ms. Andrews spent 17 years with Pfizer, ultimately serving as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio at the time. Under her leadership, Sutent® was launched, becoming the market leader in renal cell carcinoma and a refreshed positioning of Camptosar® led to robust revenue growth after years of declining sales in colorectal cancer.
Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.
Ms. Patricia S. Andrews
Non-Executive Independent Director
Ms. Andrews is an accomplished biopharmaceutical executive and public company board member with a track record of success in corporate strategy, new product commercializations, and business development. Ms. Andrews previously served as Chief Executive Officer for Sumitomo Pharma Oncology, Inc. (SMP Oncology), a clinical-stage research and development biopharmaceutical company, and Global Head of Oncology, Executive Officer for Sumitomo Pharma Co., Ltd. from 2017 to 2023. Under her leadership, the organization completed three Phase 3 trials and expanded the clinical pipeline from two programs to eight.
Prior to SMP Oncology, Ms. Andrews served as Chief Commercial Officer for Incyte and led the organization through the launch preparations and introduction of Jakafi®, the company’s first commercial product, a novel, first-in-class, first-in-disease agent for the treatment of myelofibrosis. While with Incyte, she also steered landmark licensing arrangements with Novartis and Eli Lilly that were critically important to fund the company’s long-term trajectory.
Prior to Incyte, Ms. Andrews spent 17 years with Pfizer, ultimately serving as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio at the time. Under her leadership, Sutent® was launched, becoming the market leader in renal cell carcinoma and a refreshed positioning of Camptosar® led to robust revenue growth after years of declining sales in colorectal cancer.
Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.
Mr. Pradeep Kumar Sinha
Non-Executive Independent Director
Mr. Pradeep Kumar Sinha is a Non-Executive Independent Director at Glenmark Pharmaceuticals. He joined the Indian Administrative Service in 1977. In the formative years, he served in Uttar Pradesh. Thereafter, he served with the Government of India and rose to the highest position of Cabinet Secretary, the head of civil services. He served as the Cabinet Secretary for more than 4 years before moving to the Prime Minister’s Office.
He retired from there in March 2021 after 44 years of continuous service to the nation. With the Government of India, he worked mostly in the Power and Oil & Gas (Petroleum) Ministries for about 15 years. Notable positions held with the Government of India include: Financial Advisor and Special Secretary – Petroleum and Natural Gas, Secretary – Ports and Shipping, and Secretary – Power.
He has been a Government Nominee Director in numerous major Public Sector Undertakings, including ONGC, IOCL, HPCL, BPCL, and GAIL, and is therefore well versed with the principles of healthy corporate governance. He was on the Board of Indian Oil Corporation (IOCL) for 7 years, and on the Boards of BPCL and HPCL for 6 years each.
Mr. Pradeep Kumar Sinha
Non-Executive Independent Director
Mr. Pradeep Kumar Sinha is a Non-Executive Independent Director at Glenmark Pharmaceuticals. He joined the Indian Administrative Service in 1977. In the formative years, he served in Uttar Pradesh. Thereafter, he served with the Government of India and rose to the highest position of Cabinet Secretary, the head of civil services. He served as the Cabinet Secretary for more than 4 years before moving to the Prime Minister’s Office.
He retired from there in March 2021 after 44 years of continuous service to the nation. With the Government of India, he worked mostly in the Power and Oil & Gas (Petroleum) Ministries for about 15 years. Notable positions held with the Government of India include: Financial Advisor and Special Secretary – Petroleum and Natural Gas, Secretary – Ports and Shipping, and Secretary – Power.
He has been a Government Nominee Director in numerous major Public Sector Undertakings, including ONGC, IOCL, HPCL, BPCL, and GAIL, and is therefore well versed with the principles of healthy corporate governance. He was on the Board of Indian Oil Corporation (IOCL) for 7 years, and on the Boards of BPCL and HPCL for 6 years each.
Ms. Vijayalakshmi Iyer
Non-Executive Independent Director
Mrs. Vijayalakshmi Iyer is a Non-Executive Independent Director at Glenmark Pharmaceuticals. She has nearly four decades of experience in the banking and finance sector in India.
She retired as the Chairman and Managing Director of Bank of India in May 2015, where she played an instrumental role in structuring it as an umbrella institution offering a diverse range of banking and financial services.
She also served as a member (finance and investment) at IRDAI from 2015 to 2017, where she played a significant role in the introduction and amendment of various regulations related to, inter alia, finance and accounts, corporate governance, mergers and acquisition, registration of new insurance companies and exposure of management.
Ms. Vijayalakshmi Iyer
Non-Executive Independent Director
Mrs. Vijayalakshmi Iyer is a Non-Executive Independent Director at Glenmark Pharmaceuticals. She has nearly four decades of experience in the banking and finance sector in India.
She retired as the Chairman and Managing Director of Bank of India in May 2015, where she played an instrumental role in structuring it as an umbrella institution offering a diverse range of banking and financial services.
She also served as a member (finance and investment) at IRDAI from 2015 to 2017, where she played a significant role in the introduction and amendment of various regulations related to, inter alia, finance and accounts, corporate governance, mergers and acquisition, registration of new insurance companies and exposure of management.
Ms. B. E. Saldanha
Non-Executive Independent Director
Mrs. B. E. Saldanha is a Non-Executive Director and a member of the promoter group of Glenmark Pharmaceuticals. Prior to this, she was the Director for Exports and managed Glenmark’s international operations from 1982 to 2005.
During her 23-year tenure with the organization, she was responsible for developing and growing the company’s export business.
Ms. B. E. Saldanha
Non-Executive Independent Director
Mrs. B. E. Saldanha is a Non-Executive Director and a member of the promoter group of Glenmark Pharmaceuticals. Prior to this, she was the Director for Exports and managed Glenmark’s international operations from 1982 to 2005.
During her 23-year tenure with the organization, she was responsible for developing and growing the company’s export business.